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Abstract
There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncol-
ogy for specific entities such as ALK-driven inflammatory myofibroblastic tumor (IMT). IMT
treatment can be challenging due to localization of the tumor and in rare cases of metastasis.
When standard surgical treatment is not feasible, ALK inhibitors may play an important role,
as recently reported for the first-generation ALK inhibitors (crizotinib). However, data on the
second-generationALK inhibitors are limited.We report twoemblematic cases of IMT in pediatric
patients, treatedwith the second-generationALK inhibitor ceritinib in the context of a clinical trial
(NCT01742286).
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1 INTRODUCTION
There is an increasing interest in anaplastic lymphoma kinase (ALK)
inhibitors for treatment of pediatric malignancies that are ALK or ROS
fusion gene driven, among others inflammatorymyofibroblastic tumor
(IMT) andanaplastic large-cell lymphoma, as recently highlighted in the
report from the Paediatric Strategy Forum for ALK Inhibition.1
IMT is amesenchymal neoplasm characterized by a spindle cell pro-
liferation with an inflammatory infiltrate, occurring primarily during
the first two decades of life. Rearrangements involving the ALK locus
have been documented in approximately 50% of IMTs and may define
a subgroup of IMTs sensitive to targeted kinase inhibition.2
Although IMT are considered by theWorld Health Organization to
be of “intermediatemalignancy”, treatment can be challenging because
of the localization of the tumor, leading to difficult or impossible sur-
gical resection with potentially severe mutilation. Moreover, in rare
cases, metastasis can occur.3 When standard surgical treatment is not
feasible, ALK inhibitors may play an important role in reducing tumor
volume. A Children's Oncology Group (COG) report and a recently
published review show the promising efficacy of the first-generation
ALK inhibitors (crizotinib) in IMT.2,4 In addition, case reports on a few
patients treated with ceritinb have been published.5–8
Abbreviations: ALK, anaplastic lymphoma kinase; CML, chronic myeloid leukemia; COG, Children's Oncology Group; CR, complete remission; IMT, inflammatorymyofibroblastic tumor; PR,
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We here report on two emblematic cases of IMT in pediatric
patients, treated with the second-generation ALK inhibitor ceritinib in
the context of a clinical trial (NCT01742286).
2 CASE REPORTS
2.1 Patient 1
The first case is a stage 4 IMT, initially presenting in a 9-year-old
male child patient, with a primary lesion in the elbow region. Over a
time period of 8 years, the patient was offered various lines of treat-
ment, including nonradical resection, as well as non-steroidal anti-
inflammatory drugs and metronomic chemotherapy with methotrex-
ate and vinorelbine. When the patient was 17 years old, a stage 4
relapse with lung metastasis was detected. FISH on archived tumor
material revealed the presence of anALK translocation, and the patient
started treatment with the second-generation ALK inhibitor ceri-
tinib at a dose of 300 mg/m2/day (500 mg/day). A response was evi-
dent after 6 weeks of treatment, and a complete remission (CR) was
reached in 6 months, with almost full regression of lung metastasis
on computed tomography (CT) scans. After 2 years of treatment with
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F IGURE 1 Patient 1—A,Magnetic resonance imaging at second
local relapse of the inflammatorymyofibroblastic tumor in the elbow;
B, regression after 2months of treatment with ceritinib
persistentCR, anelectivediscontinuationof treatmentwas attempted,
but unfortunately after 2months a local relapse was evident, also with
renewed progression of the lung metastasis. Ceritinib was restarted
at a dose of 600 mg/day, outside the clinical trial. This led again to
CR after 2 months of treatment (Figure 1). The only side effects that
occurred were mild gastrointestinal complaints and an increase in
serum creatinine (maximum grade 1—starting from 0.7 mg/dL, going
up to a maximum of 1.3 mg/dL), with a rapid recovery during treat-
ment discontinuation (decreased to 0.9 mg/dL). The effect on creati-
nine values has already been reported for other ALK inhibitors like
crizotinib and might be related to interference with the tubular secre-
tion of creatinine.9 Considering the side effects and the fast complete
response, the dose was reduced to 450 mg/day, which was safely con-
tinued till now. Currently, the patient is 22 years old and in CR for 3
years since the therapy was restarted.
2.2 Patient 2
The second case is a 14-year-old male patient presenting with persis-
tent hematuria anddiagnosedwith an IMT localized in thebladderwall.
FISH was positive for an ALK translocation in approximately 50% of
the tumor cells, and immunohistochemistry showed ALK expression.
To avoid a destructive surgical resection, neo-adjuvant treatment with
ceritinibwas attempted at the dosage of 450mg/m2/day (800mg/day).
After 2 months of treatment, the patient experienced a severe
toxicity with acute liver and renal failure, which led to a prompt and
definitive discontinuation of treatment with ceritinib. The maximum
level of transaminases that was reached was 15,000 U/L for glutamic
oxaloacetic transaminase and 8,600 U/L for glutamic pyruvic transam-
inase (≫ 10×ULN, where ULN is upper limit of normal), with a total
bilirubin level of 4 mg/dL (> 3 × ULN). No infections were demon-
strated, and other possible causeswere excluded by imaging and blood
tests. We concluded this might be a case of drug-induced liver injury
(Hy's Law), as already reported for othersALK inibitors.10,11 Moreover,
tyrosine kinase inhibitors (TKIs) can inhibit paracetamol glucuronida-
tion, and the interaction of the two drugs may have played a role in
our patient, who was taking paracetamol for preexisting “abdominal
pain”.12 Despite extensive infectious work-up which was negative, a
viral infection may also have played a role, as the patient was suffering
from a common cold. One month after the start of symptoms, a com-
plete recovery from hepatic injury was obtained. At this point, after 2
months of treatment and 1 month of wash-out due to the toxicity, a
magnetic resonance imaging evaluation revealed a 70% reduction of
the tumor size, and the patient underwent complete surgical resection
preserving the integrity of thebladder (Figure2). Currently, thepatient
is in continuous CR now 3 years from surgical resection, without any
additional treatment andwith normal liver function.
3 DISCUSSION
These twocases showthedifferent important roleofALK inhibitors for
IMT treatment strategy as neo-adjuvant treatment and for metastatic
disease.
Promising activity was recently reported in a COG study on ALK
inhibition with crizotinib, including 14 IMT patients. This Phase I/II
trial showed CR or partial remission (PR) in 36% and 50% of patients
with either metastatic or inoperable ALK-positive IMT. At the time
of the study report, 10 out of 12 patients in CR or PR discontin-
ued treatment, but the follow up is not reported, thus it is unknown
if these patients subsequently relapsed or not.2 In addition, a retro-
spective collection of 30 IMT cases from the literature (including the
above-mentioned study) showed CR in 40% and PR in another 40%
of patients, after treatment with crizotinib. All the patients reported
had an unresectable or multifocal disease, representing a subgroup in
F IGURE 2 Patient 2—A, Inflammatorymyofibroblastic tumor of the bladder at diagnosis; 2, reduction of tumor size after 3months of therapy
with ceritinib; C, complete resection after surgery
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which ALK inhibitors may play a crucial role. Again, the follow-up after
crizotinib discontinuation, if occurred, was not reported.4
One of the major limitations of ALK inhibitors is acquired tumor
cells resistance developed during treatment.13 This occurred also in
two patients treated for IMT with crizotinib and reported by Thailen
et al., showing a progression of disease after 2 and 8months of contin-
uous treatment.4 Nevertheless, our first case suggests the existence of
a pattern already known for other diseases, such as in chronic myeloid
leukemia (CML), where patients who electively discontinue TKIs after
achieving long-lasting completemolecular remission and subsequently
fail during the treatment-free periodmight remain sensitive to retreat-
ment with the same inhibitor.14 This case reveals the intriguing
possibility that the experience in CML could be potentially translated
to ALK inhibition in IMT, which is probably also mainly driven by the
ALK fusion as a “monogenic” event.
The second patient shows the potential of ALK inhibitors in newly
diagnosed and/or relapsed unresectable disease. Recently, another
case report highlighted the efficacy of ALK inhibitors (crizotinib) as
neo-adjuvant treatment in an IMT of the urinary bladder, resulting
in avoidance of radical cystectomy in a 17-year-old patient.15 Fur-
ther investigations need to be performed in newly diagnosed and/or
relapsed unresectable IMTs with ALK inhibitors to see whether this
results in higher cure rates by increasing the rate of radical surgical
resections with less mutilation. A study with crizotinib in this respect
is underway (EudraCT number 2015-005437-53).
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